New drug combo aims to tame immune attack after stem cell transplants

NCT ID NCT06815003

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding vedolizumab to standard drugs (cyclophosphamide and tacrolimus) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia and myelodysplastic syndrome. GVHD occurs when donor immune cells attack the recipient's body. Vedolizumab is an antibody that may reduce gut inflammation, while the other drugs suppress the immune system. The study enrolls 35 adults aged 18 to 80 and monitors for side effects, engraftment failure, and GVHD-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vedolizumab, cyclophosphamide, tacrolimus
What this could lead to: If successful, this combination could lower the risk of graft-versus-host disease, a serious complication of stem cell transplants, improving outcomes for people with blood cancers.
What could go wrong: This is an early-phase trial with only 35 participants, so results may not apply to everyone. The drugs can cause serious side effects like infections and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndrome Myelodysplastic Syndromes Myeloproliferative Disorders myeloproliferative neoplasm Precursor Cell Lymphoblastic Leukemia-Lymphoma graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA GRAFT-VERSUS-HOST DISEASE MYELODYSPLASTIC SYNDROME MYELOPROLIFERATIVE NEOPLASM

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.